1. A method of treating a proliferative disease in an individual, comprising administering to the individual a) an effective amount of a nanoparticle composition comprising a taxane and a carrier protein, and b) an effective amount of an anti-VEGF antibody, wherein the effective amount of taxane in the nanoparticle composition is from about 45 mg / ppm to about 350 mg / m, and an effective amount of an anti-VEGF antibody is from more than 1 mg / kg to less than 10 mg / kg or from more than 15 mg / kg to less than 20 mg / kg. 2. The method of claim 1, wherein the proliferative disease is cancer. The method of claim 2, wherein the cancer is breast cancer. The method of claim 1, wherein the anti-VEGF antibody is bevacizumab. 5. The method of claim 1, wherein the effective amount of the anti-VEGF antibody is about 6 mg / kg. The method of claim 1, wherein the effective amount of the anti-VEGF antibody is about 8 mg / kg. The method of claim 1, wherein the effective amount of taxane in the nanoparticle composition is from about 80 mg / md to about 150 mg / mtaxan in the nanoparticle composition. The method of claim 1, wherein the effective amount of taxane in the nanoparticle composition is from about 200 mg / mt to about 350 mg / mtaxan in the nanoparticle composition. The method of claim 1, wherein the nanoparticle-containing composition and anti-VEGF antibody are administered to the individual sequentially. The method of claim 1, wherein the nanoparticle-containing composition is administered for at least one cycle prior to administration of an anti-VEGF antibody. The method of claim 10, wherein the introduction of the nanoparticle-containing composition with1. Способ лечения пролиферативного заболевания у индивидуума, включающий введение индивидууму а) эффективного количества композиции, содержащей наночастицы, включающие таксан и белок-носитель, и b) эффективного количества антитела против VEGF, причем эффективное количество таксана в содержащей наночастицы композиц
